{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:54:58Z","timestamp":1775814898708,"version":"3.50.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic, pre-malignant disorders characterized by monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage. Recent advances in the pathogenesis, natural history, and prognosis of MGUS and SMM are reviewed. A new risk stratification system to determine the prognosis of MGUS using the size and type of M protein, and the serum free light chain assay is discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.340","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"340-345","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management"],"prefix":"10.1182","volume":"2005","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111701572370600_R1","unstructured":"Kyle RA, Rajkumar SV: Plasma cell disorders. In Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W. B. Saunders; 2004:1184\u20131195."},{"key":"2019111701572370600_R2","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860\u20131873.","DOI":"10.1056\/NEJMra041875"},{"key":"2019111701572370600_R3","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc. 2003;78:21\u201333.","DOI":"10.4065\/78.1.21"},{"key":"2019111701572370600_R4","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2019111701572370600_R5","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274\u20131276.","DOI":"10.1038\/sj.leu.2402183"},{"key":"2019111701572370600_R6","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u2013569.","DOI":"10.1056\/NEJMoa01133202"},{"key":"2019111701572370600_R7","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.[see comment]. Mayo Clin Proc. 2004;79:859\u2013866.","DOI":"10.4065\/79.7.859"},{"key":"2019111701572370600_R8","unstructured":"Weber D, Wang LM, Delasalle K, Smith T, Alexanian R. Risk factors for early progression of asymptomatic multiple myeloma. Hematology J. 2003;4 (Suppl 1):S31."},{"key":"2019111701572370600_R9","unstructured":"Wang M, Alexanian R, Delasalle K, Weber D. Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. Blood. 2003;102:687a."},{"key":"2019111701572370600_R10","doi-asserted-by":"crossref","unstructured":"Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546\u20131558.","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"2019111701572370600_R11","doi-asserted-by":"crossref","unstructured":"Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nature Rev Cancer. 2002;2:175\u2013187.","DOI":"10.1038\/nrc746"},{"key":"2019111701572370600_R12","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611\u20135622.","DOI":"10.1038\/sj.onc.1204641"},{"key":"2019111701572370600_R13","doi-asserted-by":"crossref","unstructured":"Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417\u20131424.","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424"},{"key":"2019111701572370600_R14","unstructured":"Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210\u20132216."},{"key":"2019111701572370600_R15","doi-asserted-by":"crossref","unstructured":"Galea HR, Cogne M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exper Immunolo. 2002;129:247\u2013253.","DOI":"10.1046\/j.1365-2249.2002.01929.x"},{"key":"2019111701572370600_R16","unstructured":"Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003."},{"key":"2019111701572370600_R17","doi-asserted-by":"crossref","unstructured":"Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101:1715\u20131717.","DOI":"10.1182\/blood-2002-08-2441"},{"key":"2019111701572370600_R18","doi-asserted-by":"crossref","unstructured":"Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104:1159\u20131165.","DOI":"10.1182\/blood-2003-11-3811"},{"key":"2019111701572370600_R19","doi-asserted-by":"crossref","unstructured":"Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17:2025\u20132031.","DOI":"10.1038\/sj.leu.2403084"},{"key":"2019111701572370600_R20","doi-asserted-by":"crossref","unstructured":"Kumar S, Witzig TE, Wellik L, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004;18:624\u2013627.","DOI":"10.1038\/sj.leu.2403285"},{"key":"2019111701572370600_R21","doi-asserted-by":"crossref","unstructured":"Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Min Res. 2002;17:1921\u20131925.","DOI":"10.1359\/jbmr.2002.17.11.1921"},{"key":"2019111701572370600_R22","unstructured":"Roodman GD. Mechanisms of bone metastasis.[see comment]. N Engl J Med. 2004;350:1655\u20131664."},{"key":"2019111701572370600_R23","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among Olmsted County, MN residents 50 years of age. Blood. 2003;102:934a (A3476)."},{"key":"2019111701572370600_R24","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood. 2005;106:812\u2013817.","DOI":"10.1182\/blood-2005-03-1038"},{"key":"2019111701572370600_R25","doi-asserted-by":"crossref","unstructured":"Kyle RA. \u201cBenign\u201d monoclonal gammopathy\u2014after 20 to 35 years of follow-up. Mayo Clin Proc. 1993;68:26\u201336.","DOI":"10.1016\/S0025-6196(12)60015-9"},{"key":"2019111701572370600_R26","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037\u20132044.","DOI":"10.1182\/blood.V96.6.2037"},{"key":"2019111701572370600_R27","doi-asserted-by":"crossref","unstructured":"Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347\u20131349.","DOI":"10.1056\/NEJM198006123022405"},{"key":"2019111701572370600_R28","doi-asserted-by":"crossref","unstructured":"Witzig TE, Kyle RA, WM OF, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma. Br J Haematol. 1994;87:266\u2013272.","DOI":"10.1111\/j.1365-2141.1994.tb04908.x"},{"key":"2019111701572370600_R29","doi-asserted-by":"crossref","unstructured":"Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625\u20131634.","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"2019111701572370600_R30","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. Update on smoldering multiple myeloma. Haematologica. 2005;90 (Suppl 1):12.","DOI":"10.1007\/978-3-662-08885-2_1"},{"key":"2019111701572370600_R31","doi-asserted-by":"crossref","unstructured":"Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900\u20132902.","DOI":"10.1182\/blood.V97.9.2900"},{"key":"2019111701572370600_R32","doi-asserted-by":"crossref","unstructured":"Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48:655\u2013657.","DOI":"10.1093\/clinchem\/48.4.655"},{"key":"2019111701572370600_R33","doi-asserted-by":"crossref","unstructured":"Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437\u20131444.","DOI":"10.1093\/clinchem\/48.9.1437"},{"key":"2019111701572370600_R34","doi-asserted-by":"crossref","unstructured":"Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23:5668\u20135674.","DOI":"10.1200\/JCO.2005.03.159"},{"key":"2019111701572370600_R35","unstructured":"Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89:717\u2013741."},{"key":"2019111701572370600_R36","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775\u2013779.","DOI":"10.1038\/sj.leu.2402866"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/340\/645020\/340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/340\/645020\/340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T15:23:17Z","timestamp":1683300197000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/340\/19260\/MGUS-and-Smoldering-Multiple-Myeloma-Update-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.340","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}